Kai Kang

Orcid: 0000-0001-7936-8569

Affiliations:

Sichuan University, Division of Thoracic Tumor Multimodality Treatment, Chengdu, China
West China Hospital, Laboratory of Clinical Cell Therapy, Cancer Center, China

According to our database¹, Kai Kang authored at least 5 papers between 2023 and 2025.

Collaborative distances:

Dijkstra number² of five.
Erdős number³ of five.

Timeline

Legend:

Book In proceedings Article PhD thesis Dataset Other

Bibliography

2025

Cross-tissue Atlas of Mucosa-associated Lymphoid Tissue Lymphomas Reveals Intratumoral Heterogeneity and Microenvironmental Subtypes.

[BibT_eX]

[DOI]

Dataset, September, 2025

SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis.

[BibT_eX]

[DOI]

Dataset, August, 2025

SBRT embedded in low-dose RT plus αPD-1 elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis.

[BibT_eX]

[DOI]

Dataset, August, 2025

2024

Rare and complex diseases in focus: ChatGPT's role in improving diagnosis and treatment.

[BibT_eX]

[DOI]

Frontiers Artif. Intell., 2024

2023

Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.

[BibT_eX]

[DOI]

Comput. Biol. Medicine, May, 2023

Kai Kang

Timeline

Legend:

Links

Online presence:

On csauthors.net:

Bibliography

Loading...